Use of approved Lu-177 radiopharmaceuticals in patients with end-stage renal disease: A review of the literature and proposed treatment algorithm.
J Neuroendocrinol
; 36(6): e13393, 2024 06.
Article
in En
| MEDLINE
| ID: mdl-38622851
ABSTRACT
Peptide receptor radionuclide therapy (PRRT) can be a very useful treatment for patients with neuroendocrine neoplasms and metastatic castration-resistant prostate cancer but it is routinely avoided in those with advanced kidney disease because it can adversely affect the renal function. Accordingly, no clear guidelines exist on the use of PRRT for patients on hemodialysis (HD). We performed a literature review to identify publications on HD patients who received PRRT with Lutetium-177 (Lu177) Dotatate and Y-90 and obtained information on Lu177 pharmacokinetics and early testing data from the manufacturer. We also perused the most recent North American Neuroendocrine Tumor Society (NANETS)/European Neuroendocrine Tumor Society (ENETS) recommendations. Seven relevant publications with a total of 15 patients were included. Patients received dose-adjusted fractions of PRRT with HD occurring usually within 24 h. There were no immediate or long-term serious adverse events attributed to the radioligand, although data was limited. Using available evidence and input from a multidisciplinary group, we have created an institutional workflow. Dose-adjusted PRRT can be offered to patients undergoing HD under careful, multidisciplinary supervision.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neuroendocrine Tumors
/
Radiopharmaceuticals
/
Kidney Failure, Chronic
/
Lutetium
Limits:
Humans
/
Male
Language:
En
Journal:
J Neuroendocrinol
Journal subject:
ENDOCRINOLOGIA
/
NEUROLOGIA
Year:
2024
Document type:
Article
Affiliation country: